✦ LIBER ✦

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

✍ Scribed by Thatcher, Nick (author);Chang, Alex (author);Parikh, Purvish (author);Rodrigues Pereira, José (author);Ciuleanu, Tudor (author);von Pawel, Joachim (author);Thongprasert, Sumitra (author);Tan, Eng Huat (author);Pemberton, Kristine (author);Archer, Venice (author);Carroll, Kevin (author)

Book ID: 117290457
Publisher: Elsevier BV
Year: 2005
Tongue: English
Weight: 158 KB
Volume: 366
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(05)67625-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pr4 ISEL: A Phase III survival study com

Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens

✍ Thatcher, N.; Chang, A.; Parikh, P.; Pemberton, K.; Archer, V. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Quality of life and survival in patients

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial

✍ M Helsing; B Bergman; L Thaning; U Hero 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 194 KB

A prospective randomized trial of Taxote

A prospective randomized trial of Taxotere versus best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: Survival update

✍ Shepherd, F; Dancey, J; Ramlau, R; Mattson, K; Gralla, R; Kim, Y; Berille, J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Quality of life assessment of second-lin

Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial

✍ Dancey, J 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Rationale and Design of MARQUEE: A Phase

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB

Quality of life in patients with advance

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

✍ Chandra P Belani; Thomas Brodowicz; Tudor E Ciuleanu; Maciej Krzakowski; Sung Hy 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 230 KB